Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Seagen
→
Pfizer

Acquisition · Cash + Stock · announced Mar 13, 2023

View in network
  1. Announced

    Mar 13, 2023

  2. Closed

    Dec 14, 2023

Economics

Cash + Stock()

Pre-deal · pre-deal mark: 2023, year precision · rounding grid ±$100M · Pfizer 8-K filing, SEC EDGAR — Seagen acquisition (NASDAQ:SGEN market cap)

$229/share, ~$43B enterprise value

Target

Seagen

Precision Medicine · Clinical / therapeutic

HQ Bothell, WA · Founded 1998

Antibody-drug conjugate (ADC) oncology platform — Adcetris, Padcev, Tukysa (HER2+ breast cancer), and Tivdak (cervical cancer)

  • SEC EDGAR — Pfizer 8-K (Mar 13, 2023)
  • Business Wire — Pfizer/Seagen merger announcement (Mar 13, 2023)
  • SEC EDGAR — Pfizer 8-K completion (Dec 14, 2023)

Acquirer

Pfizer

Healthcare

HQ New York, NY

Global pharmaceutical and biotechnology company — oncology portfolio includes breast cancer therapies via Seagen ADC platform

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Largest oncology M&A in history — Seagen's ADC platform (Adcetris, Padcev, Tukysa, Tivdak) transforms Pfizer into top-tier oncology company; Tukysa targets HER2+ breast cancer, Tivdak targets cervical cancer

Evidence ladder

Dual-source corroborationValue disclosed
  1. Primary (regulatory / filing)

    SEC EDGAR — Pfizer 8-K (Mar 13, 2023)

  2. Secondary (press / IR)

    Business Wire completion announcement (Dec 14, 2023)

  3. Primary (regulatory / filing)

    SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/78003/000119312523068538/d408093d8k.htm

    Open source

Limitations

  • $229/share, ~$43B enterprise value
  • Pre-deal valuation sourced from: Pfizer 8-K filing, SEC EDGAR — Seagen acquisition (NASDAQ:SGEN market cap). Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Precision Medicine

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Why included
Varian Medical SystemsSiemens HealthineersAug 2, 2020same evidence class

Same-sector adjacency — not valuation peers

These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.

Vs this deal
GRAILIlluminaSep 21, 2020

Other verified deals by Pfizer

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by Pfizer are already listed above, or none are in the dataset.

Patient empowerment context

Empowerment context — Seagen

Curated survey mapping

HLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.

  • Presented with clinical trial as treatment option (Press release)1 in 5cited HLTH 2022Mapping source →
  • No survivorship care plan after active treatment (Press release)54%cited HLTH 2022Mapping source →
  • Oncologist listens; wishes reflected in treatment plan (Press release)56%cited HLTH 2022Mapping source →
  • Not aware of survivorship resources (Press release)2 in 3cited HLTH 2022Mapping source →

Other curated mappings on these gaps: Biotheranostics, Genomic Health, Foundation Medicine, Flatiron Health

Full cited gap matrix →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.